Company Valuation: Vector Science and Therapeutics Corp.

Data adjusted to current consolidation scope
Fiscal Period: August 2025
Market Cap 1 0.1109
Change -
Enterprise Value (EV) 1 -2.771
Change -
P/E -0.29x
PBR 0.15x
PEG -
Capitalization / Revenue -
EV / Revenue -
EV / EBITDA -
EV / EBIT 6.06x
EV / FCF -
FCF Yield -
Dividend per Share 2 -
Rate of return -
EPS 2 -0.1292
Distribution rate -
Net sales -
EBITDA -
EBIT 1 -0.4571
Net income 1 -0.898
Net Debt 1 -2.882
Reference price 2 0.037
Nbr of stocks (in thousands) 3,000
Announcement Date 14/04/26
1USD in Million2USD
Estimates


P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- - - - 19Cr
11.86x1.23x5.32x2.45% 1.66TCr
7.93x14.95x - -.--% 1.56TCr
28.57x7.02x14.15x2.54% 1.21TCr
Average 16.12x 7.73x 9.74x 1.66% 1.11TCr
Weighted average by Cap. 15.04x 7.64x 9.04x 1.61%

Y-o-Y evolution of P/E

Valuation ratios - P/E - Vector Science and Therapeutics Corp.

Historical PBR trend

Valuation ratios - PBR - Vector Science and Therapeutics Corp.

Evolution Enterprise Value / Sales

Valuation ratios - VE_REV - Vector Science and Therapeutics Corp.

Change in Enterprise Value/EBITDA

Valuation ratios - VE_EBITDA - Vector Science and Therapeutics Corp.

  1. Stock Market
  2. Stocks
  3. PAIN Stock
  4. Valuation Vector Science and Therapeutics Corp.